IRIS
RIMINI, MARGHERITA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.717
AS - Asia 1.514
EU - Europa 900
SA - Sud America 409
AF - Africa 33
OC - Oceania 5
Totale 4.578
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.646
SG - Singapore 633
CN - Cina 467
BR - Brasile 343
RO - Romania 263
IT - Italia 218
HK - Hong Kong 159
VN - Vietnam 135
DE - Germania 91
SE - Svezia 71
RU - Federazione Russa 56
GB - Regno Unito 51
CA - Canada 36
AR - Argentina 29
IN - India 29
MX - Messico 26
AT - Austria 25
FR - Francia 25
NL - Olanda 22
JP - Giappone 21
PL - Polonia 21
FI - Finlandia 20
BD - Bangladesh 17
ZA - Sudafrica 17
ES - Italia 11
ID - Indonesia 10
IQ - Iraq 10
CL - Cile 9
LT - Lituania 9
CO - Colombia 7
EC - Ecuador 7
IE - Irlanda 6
TR - Turchia 6
AU - Australia 5
EG - Egitto 5
MA - Marocco 5
UY - Uruguay 5
BE - Belgio 4
PK - Pakistan 4
PH - Filippine 3
TT - Trinidad e Tobago 3
UZ - Uzbekistan 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
HN - Honduras 2
IR - Iran 2
KW - Kuwait 2
PY - Paraguay 2
UA - Ucraina 2
AL - Albania 1
AO - Angola 1
BB - Barbados 1
BW - Botswana 1
BY - Bielorussia 1
CG - Congo 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
GA - Gabon 1
GT - Guatemala 1
GY - Guiana 1
IL - Israele 1
JM - Giamaica 1
KE - Kenya 1
KG - Kirghizistan 1
KR - Corea 1
KZ - Kazakistan 1
LB - Libano 1
MY - Malesia 1
NP - Nepal 1
OM - Oman 1
PE - Perù 1
RS - Serbia 1
TW - Taiwan 1
Totale 4.578
Salva come PNG Salva come JPEG
Città #
Dallas 940
Singapore 351
Hong Kong 159
Ashburn 151
Beijing 125
New York 77
Shanghai 70
Hefei 64
Ho Chi Minh City 57
Los Angeles 51
Milan 44
São Paulo 29
Munich 27
Boardman 26
Hanoi 26
Moscow 23
Rome 22
Lawrence 19
Princeton 19
Tokyo 19
Warsaw 19
Montreal 18
Nuremberg 18
Poplar 18
Stockholm 18
Cesano Boscone 17
Santa Clara 17
Helsinki 15
London 15
Vienna 15
Brooklyn 14
Orem 14
Denver 13
Mexico City 13
Romagnano Sesia 13
Frankfurt am Main 12
Manchester 12
Rio de Janeiro 12
Chicago 11
Guangzhou 11
Johannesburg 11
Biên Hòa 10
Boston 10
Toronto 10
Chennai 9
Houston 9
Phoenix 9
Atlanta 8
Bologna 7
Da Nang 7
Naples 7
Amsterdam 6
Bacoli 6
Dublin 6
Falkenstein 6
Porto Alegre 6
Washington 6
Belo Horizonte 5
Brasília 5
Buenos Aires 5
Montevideo 5
Querétaro 5
Seattle 5
Ankara 4
Assago 4
Brisbane 4
Brussels 4
Changsha 4
Columbus 4
Dhaka 4
Haiphong 4
Joinville 4
Lappeenranta 4
Londrina 4
Monza 4
Mumbai 4
Niterói 4
Pelotas 4
Quinta Normal 4
Salvador 4
San Francisco 4
Sumaré 4
The Dalles 4
Wolfhagen 4
Cairo 3
Calgary 3
Campinas 3
Can Tho 3
Cape Town 3
Catania 3
Chongqing 3
Cleveland 3
Contagem 3
Curitiba 3
Duque de Caxias 3
Erbil 3
Gravataí 3
Guarulhos 3
Harbin 3
Helena 3
Totale 2.889
Salva come PNG Salva come JPEG
Nome #
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab 387
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 370
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study 314
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 84
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab 79
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents 77
Combined hepatocellular-cholangiocarcinoma: morpho-molecular updates and considerations 76
Combined Loco-Regional and Systemic Treatment Strategies for Hepatocellular Carcinoma: From Basics to New Developments 74
Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art 71
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib 70
Radial and longitudinal margins in surgery of perihilar cholangiocarcinoma: When R1 definition is associated with different prognosis 65
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 65
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients 64
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study 64
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab 62
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 62
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 61
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 60
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population 59
Radioembolization for Hepatocellular Carcinoma: a Comparison on Dual-phase Cone-beam CT, Contrast-enhanced CT (CECT) and 99mTc-macroaggregated albumin-SPECT/CT in predicting final distribution volumes and dosimetry of the post-embolization 90Y PET/CT 57
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 57
Angiogenesis in biliary tract cancer: targeting and therapeutic potential 55
Cholangiocarcinoma: new perspectives for new horizons 55
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience 55
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 53
Treatment options for advanced hepatocellular carcinoma: the potential of biologics 52
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions 51
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis? 49
Identification of Atezolizumab Plus Bevacizumab Prognostic Index via Recursive Partitioning Analysis in HCC: The ABE Index 49
Intermediate hepatocellular carcinoma: new horizons and prospects for our patients 48
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters 46
The oncologic burden of residual disease in incidental gallbladder cancer: An elastic net regression model to profile high-risk features 46
The prognostic value of the new combined hemo-eosinophil inflammation index (Hei index): A multicenter analysis of anal cancer patients treated with concurrent chemo-radiation 46
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study 46
Corrigendum to ‘Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma’ [Euro J Cancer 171 (2022) 232–241, (S0959804922002829), (10.1016/j.ejca.2022.05.004)] 44
Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib 44
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 43
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study 42
Could Inflammatory Indices and Metabolic Syndrome Predict the Risk of Cancer Development? Analysis from the Bagnacavallo Population Study 42
The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy 42
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 41
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study 41
Clinical implications of malnutrition in the management of patients with pancreatic cancer: Introducing the concept of the nutritional oncology board 41
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 40
Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications 40
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib 40
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population 39
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma 39
Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma 39
The Prognostic Role of Baseline Eosinophils in HPV-Related Cancers: a Multi-institutional Analysis of Anal SCC and OPC Patients Treated with Radical CT-RT 39
Correction to: Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis (Targeted Oncology, (2021), 16, 3, (401-410), 10.1007/s11523-021-00797-3) 39
Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis 38
Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis 38
Effects of Metformin and Vitamin D on Clinical Outcome in Cholangiocarcinoma Patients 37
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 36
Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study 36
Exceptional response to lurbinectedin and irinotecan in BRCA-mutated platinum-resistant ovarian cancer patient: a case report 35
Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution 35
Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis 35
Response to letter entitled Re: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients 34
Child Pugh and ALBI grade: past, present or future? 34
Lenvatinib as a therapy for unresectable hepatocellular carcinoma 34
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience 33
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients 33
Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting 32
Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma 32
Understanding the causes of recurrent HCC after liver resection and radiofrequency ablation 31
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 31
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma 30
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib 30
Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib 30
Anti-HER2 therapies in biliary tract cancers: A meta-analysis on disease location, HER2 status, and survival outcomes 29
Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study 29
The Prognostic Role of Early Skeletal Muscle Mass Depletion in Multimodality Management of Patients with Advanced Gastric Cancer Treated with First Line Chemotherapy: A Pilot Experience from Modena Cancer Center 28
Viral Hepatitis in Western Patients with Advanced Intrahepatic Cholangiocarcinoma: Retrospective Assessment of Prevalence, Prognostic and Predictive Significance 25
Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy 25
Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib 25
Correction: Radioembolization for Hepatocellular Carcinoma: a Comparison on Dual-phase Cone-beam CT, Contrast-enhanced CT (CECT) and 99mTc-macroaggregated albumin-SPECT/CT in predicting final distribution volumes and dosimetry of the post-embolization 90Y PET/CT 24
Why does survival of hepatocellular carcinoma patients remain so low? Key stumbling blocks and questions in preclinical and clinical development 24
Five years of lenvatinib in hepatocellular carcinoma: are there any predictive and/or prognostic factors? 24
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib 23
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population 22
External Validation of Surrogate Indices of Fatty Liver in the General Population: The Bagnacavallo Study 22
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients 21
Prognostic implication of serum AFP in patients with hepatocellular carcinoma treated with regorafenib 19
Genomic profiling of small bowel adenocarcinoma: a pooled analysis from 3 databases 18
Radial and Longitudinal Margins in Surgery of Perihilar Cholangiocarcinoma: When R1 Definition Is Associated with Different Prognosis 18
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study 17
Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience 15
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment 15
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 14
Surgery for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: milestone changes in the last two decades potentially affecting current guidelines 10
Ivosidenib for IDH1-Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real-World Study 9
Il trattamento del carcinoma squamocellulare cutaneo localmente avanzato e metastatico 8
null 7
Correction to: Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib 6
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies 5
Letter Re: Reflections on the MAGIC-D Prognostic Model in Advanced Biliary Tract Cancer 3
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 3
Totale 4.786
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.879
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.879
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215 0 0 0 0 0 4 1 0 0 0 0 0
2021/202218 0 0 0 1 0 0 2 12 2 0 0 1
2022/2023118 42 20 4 1 1 22 7 7 8 2 1 3
2023/2024224 12 3 31 18 13 50 3 15 0 5 24 50
2024/20251.228 92 27 18 13 38 91 384 140 122 79 62 162
2025/20263.193 385 685 814 737 527 45 0 0 0 0 0 0
Totale 4.786